Patients that are not profiting from different therapies might be prescribed Tasigna too. Philadelphia chromosome-positive (CML) is a long-term, treatable type of cancer which could turn into a chronic illness if not treated correctly.
Roughly 8,950 fresh cases of CML are going to be reported at the U.S. and more than one million deaths in 2017.
How Can Tasigna Work?
Tasigna belongs to a category of drugs called tyrosine kinase inhibitors and works by blocking and targeting tyrosine kinases, particular proteins responsible for its activation, signaling, and development of particular cells.
Targeted cancer therapies like Tasigna function to prevent leukemia cells by growing while reducing the probability of harm to healthy cells. To know more about Tasigna lawsuit then you can browse to Tasigna Atherosclerosis | Tasigna Peripheral Arterial Disease.
Tasigna and Atherosclerosis
Tasigna was allegedly linked to atherosclerosis, a disorder where plaque builds up inside the blood vessels. According to the National Heart, Lung, and Blood Institute, atherosclerosis may impact virtually any artery in the body, such as blood vessels in the heart, brain, arms, thighs, pelvis, and glands.
The shortage of adequate blood flow, mainly in the legs, may potentially result in serious infections and tissue death which could occasionally require amputation.
Other Vascular Risks Connected to Tasigna
Atherosclerosis can result in other diseases, such as:
- Coronary Heart Disease
- Carotid Artery Disease
- Peripheral Artery Disease
- Chronic Kidney Disease
Similarly, studies have indicated a connection between Tasigna along with other tyrosine kinase inhibitors and vascular events. Based on Hematological, evidence indicates that nilotinib includes a propensity to raise the possibility of occlusive cardiovascular disease, particularly in patients with preexisting cardiovascular risk factors.